This is the most significant quarterly in commercialising Anteo...

This is the most significant quarterly in commercialising Anteo battery and life science tech that we have ever had to date.

Anteo X-

A proven ability to be intergrated into existing scale production of slurry mix into a third party commercial anode for a major EV company no less.

Proven ability to achieve technical milestones in MOUs with both Trinseo and Wyon next step is prove it at scale and they adopt it or they move on.

Pilot production plant- completion within next week or two. This will prove scale production of Anteo X and allow much more significant orders for testing and integration to be taken. Likely one of the final steps in MOUs and proof of concept.

Silicon Anode-

Proven to be able to manufactured at scale in a commercial anode using existing production processes. The significance of this appears to have been missed. Testing of this anode will prove if this is viable as a commercial product, but my own thoughts are - would they move to this step unless all the testing of half cells/coin cells etc have proven they can achieve cycles, cost savings and density required to be of commercial significance. This is using unrefined, cheap silicon and at 70% content, if this works it will be groundbreaking (presentations this year will likely have early stage data from this). Is this being done for a potential customer say Wyon or an EV / major battery company to prove full scale production can be achieved with existing processes and to run head to head against existing anode formulations…my thoughts are yes for sure it is. Time to move out of lab scale and into proving the factory scale.

Anteobind-

Large order from Serum Institute for vaccine production looks like they are going to integrate this as part of the process going forward as this relationship has been building for sometime. Expect regular reasonable volume orders to continue from the worlds largest vaccine manufacturer.

Anteobind NXT-

Reformulation with similar/same benefits at an achievable price point to sell at scale. This is a shift that has been needed and they have made the play, expect from here forward integration by a few major test developers will now be achievable as it is now a cost benefit play not just an increased sensitivity play.

A longer term commercial strategy is playing out proving up claims, proving scale, proving integration and proving cost benefits in both sectors. Next step integration and adoption into existing/new lines in both sides and scale up.

Funding will need close attention over coming 6 months but if an upfront for supply, equity sale or a grant arrives within the next quarter it will instantly change the equation.

GLTA